Navigation Links
FDA Issues Safety Alert on Avandia

ROCKVILLE, Md., May 21, 2007-The U.S. Food and Drug Administration (FDA) is aware of a potential safety issue related to Avandia (rosiglitazone), a drug approved to treat type 2 diabetes. Safety data from controlled clinical trials have shown that there is a potentially significant increase in the risk of heart attack and heart-related deaths in patients taking Avandia. However, other published and unpublished data from long-term clinical trials of Avandia, including an interim analysis of data from the RECORD trial (a large, ongoing, randomized open label trial) and unpublished reanalyses of data from DREAM (a previously conducted placebo-controlled, randomized trial) provide contradictory evidence about the risks in patients treated with Avandia.

Patients who are taking Avandia, especially those who are known to have underlying heart disease or who are at high risk of heart attack should talk to their doctor about this new information as they evaluate the available treatment options for their type 2 diabetes.

FDA's analyses of all available data are ongoing. FDA has not confirmed the clinical significance of the reported increased risk in the context of other studies. Pending questions include whether the other approved treatment from the same class of drugs, pioglitazone, has less, the same or greater risks. Furthermore, there is inherent risk associated with switching patients with diabetes from one treatment to another even in the absence of specific risks associated with particular treatments. For these reasons, FDA is not asking GlaxoSmithKline, the drug's sponsor, to take any specific action at this time. FDA is providing this emerging information to prescribers so that they, and their patients, can make individualized treatment decisions.

"FDA remains committed to assuring that doctors and patients have the latest information available to make treatment and medication use decisions. In th
'"/>




Page: 1 2 3

Related medicine technology :

1. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
2. Managing Preanalytical Processes for Patient Safety
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes
9. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
10. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
11. Enbrel Safety Data for up to Eight Years in Patients with Juvenile Rheumatoid Arthritis Being Presented at EULAR
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: FDA Issues Safety Alert Avandia
(Date:9/4/2015)... , Sep. 04, 2015 ... announced the addition of the "Pharmacovigilance (London, ... their offering. Understanding PhV today - ... those working in Drug safety. This ... concerned with pharmacovigilance. New entrants as well as ...
(Date:9/4/2015)... MENLO PARK, Calif. , Sept. 4, 2015 ... and the "Company"), a biopharmaceutical company focused on the ... its financial results for the fiscal year ending June ... highlights and expected near-term milestones. DelMar,s ... and live webcast for investors, analysts and other interested ...
(Date:9/3/2015)... YORK , Sept. 3, 2015 ... Your New Guide to that Market, its R&D and Sales ... to assess the future of cancer-treating medicines? Visiongain,s new report ... you stay ahead. There you discover financial data, R&D trends, ... In our analysis you see forecasted sales to ...
Breaking Medicine Technology:Pharmacovigilance Course: The Principles and Practice of Global PhV for those Working in Drug Safety (London, UK - December 7-9, 2015) 2DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 2DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 3DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 4DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 5DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 6DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 7DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 8World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 2World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 3World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 4World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 5World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 6World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 7
... Researchers from the University of Cincinnati presented results ... Ray Society 2011 Annual Meeting today, demonstrating how ... exposure for breast cancer patients.   ... show the location as well as the metabolic phase ...
... YORK, May 3, 2011 Phreesia, the patient check-in ... to all primary care physicians and pediatrics practices in ... automated patient check-in solution and, through a series of ... monitoring. (Logo: http://photos.prnewswire.com/prnh/20080220/NYW106LOGO) According ...
Cached Medicine Technology:Study Shows Same Day PET-Guided Biopsy May Expedite Pre-Operative Work-up For Breast Cancer Patients and Reduce Radiation Exposure 2Phreesia Helps Practices Manage Patients with Uncontrolled Asthma 2
(Date:9/4/2015)... ... ... Lalonde Gordon ran a 44.64 seconds scorcher in the third and final ... meters final, with an impressive 44.89 seconds at the 2015 North American, Central American ... August 2015. The 44.64 time is a new NACAC Championship record. , Recent ...
(Date:9/4/2015)... Washington, DC (PRWEB) , ... September 04, 2015 ... ... dollar-wise they all pale in comparison to settlements under the Stark physician self-referral ... an upcoming Sept. 17 webinar from Atlantic Information Services, Inc. (AIS), will ...
(Date:9/4/2015)... ... September 04, 2015 , ... ... Labor Day offer that cannot be passed up. FiltersFast.com, will ship all ... air and water filtration product replacements. Take advantage of this promotion now through ...
(Date:9/4/2015)... , ... September 04, 2015 , ... Friday night, Chicago ... hosting Generation Rescue’s A Night of Hope event supporting families affected by autism, raising ... Rowena and Joe Salas, joined together at the Oscar Swan Inn to support the ...
(Date:9/3/2015)... CA (PRWEB) , ... September 03, 2015 , ... While ... as to the best practices when preparing for a bariatric procedure, some patients have ... procedure. Apart from the basic instructions typical for many types of surgery that should ...
Breaking Medicine News(10 mins):Health News:Lalonde Gordon’s Recipe Brings Home the Gold 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 3Health News:Sept. 17 Webinar to Offer Best Practices for Physician Contracts 2Health News:FiltersFast.com Wows with a Long Labor Day Weekend Shipping Offer 2Health News:Jenny McCarthy & Donnie Wahlberg Help Raise Over $200,000 For Generation Rescue’s ‘Night Of Hope’ Chicago Charity Event 2Health News:Dr. Feiz and Associates Answer August's ‘Patient Submitted Question of the Month’: “How Can I Prepare for Weight Loss Surgery” 2
... fatal cancers, according to a new case study published in ... researcher at the University of Nevada has shown that omega-3 ... golden algae oil, can save the life of a terminal ... professor of biochemistry and associate director of the Nevada Agricultural ...
... reflux disease (GERD) is increasing at a rapid rate, ... of CA: A Cancer Journal for Clinicians, published by ... that esophagus cancer is increasing at a faster rate ... the condition can be gauged from the fact that ...
... of serious outbreaks of acute watery diarrhoea among quake survivors ... efforts to provide safe water supply and sanitation in the ... been recorded among earthquake survivors in the tent camps in ... by the Oct 8 temblor. ,However, there has been ...
... who take vacations frequently are less likely to ... or tiredness and are more satisfied with their ... Marshfield Clinic studied 1,500 women recruited from the ... central Wisconsin, US, reports science portal EurekAlert., ...
... and the small difference of 2% dissimilarity between chimps and ... some of the genetic diseases which are prone to humans ... resistance and Progression of HIV to AIDS are main research ... both humans and chimpanzees have a different progression rate of ...
... had said that the cause of high death tolls ... to lack of preparedness of Indian Health Officials in ... infection is spread by transmission of Japanese Encephalitis Virus ... in the monsoon seasons. The disease symptoms are characterized ...
Cached Medicine News:Health News:Acid Reflux Increases Risk Of Esophagus Cancer 2Health News:Pakistani Quake Survivors Face Outbreak Of Diarrhea 2Health News:Frequent Vacations Ease Mental Stress 2
Based on the clinically proven ACS MULTI-LINK Stent, ULTRA is a coronary stent system specifically designed for use in larger vessels. This innovative system utilizes a unique stent pattern to give y...
The MULTI-LINK RX PENTA Coronary Stent Systems with new ACCESS-LINK Stent Design are indicated for improving coronary luminal diameter....
Take Performance to a Higher Level....
The MULTI-LINK PIXEL Coronary Stent System was designed to address the challenges of small vessel treatment in patients with abrupt or threatened abrupt closure (ATC)....
Medicine Products: